About PrognomiQ
PrognomiQ is a company based in San Mateo (United States) founded in 2020 by Philip Ma and Omid Farokhzad.. PrognomiQ has raised $102.24 million across 4 funding rounds from investors including Fidelity Investments, T. Rowe Price and Bruker. The company has 24 employees as of December 31, 2021. PrognomiQ offers products and services including Multi-Omics Tests and Proteomic Data Services. PrognomiQ operates in a competitive market with competitors including PreOmics, Vivostat, LenioBio, ACRO Biosystems and List Biological Laboratories, among others.
- Headquarter San Mateo, United States
- Employees 24 as on 31 Dec, 2021
- Founders Philip Ma, Omid Farokhzad
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Prognomiq, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$102.24 M (USD)
in 4 rounds
-
Latest Funding Round
$11.87 M (USD), Series D
Jan 02, 2026
-
Investors
Fidelity Investments
& 9 more
-
Employee Count
24
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PrognomiQ
PrognomiQ offers a comprehensive portfolio of products and services, including Multi-Omics Tests and Proteomic Data Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables early detection of diseases using integrated proteomics data.
Provides insights into disease mechanisms via large-scale protein analysis.
Unlock access to complete
Unlock access to complete
Funding Insights of PrognomiQ
PrognomiQ has successfully raised a total of $102.24M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $11.87 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series D — $11.9M
-
First Round
First Round
(15 Mar 2022)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2026 | Amount | Series D - PrognomiQ | Valuation |
investors |
|
| Aug, 2025 | Amount | Series D - PrognomiQ | Valuation |
investors |
|
| Aug, 2024 | Amount | Series D - PrognomiQ | Valuation | Seer |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in PrognomiQ
PrognomiQ has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, T. Rowe Price and Bruker. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is provided to biomedical technology startups.
|
Founded Year | Domain | Location | |
|
Venture capital investments in healthcare are focused on by aMoon.
|
Founded Year | Domain | Location | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by PrognomiQ
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - PrognomiQ
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Prognomiq Comparisons
Competitors of PrognomiQ
PrognomiQ operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PreOmics, Vivostat, LenioBio, ACRO Biosystems and List Biological Laboratories, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Reagents and instruments for proteomics research are supplied by PreOmics.
|
|
| domain | founded_year | HQ Location |
On-site fibrin sealant preparation systems are developed and provided.
|
|
| domain | founded_year | HQ Location |
Kits for cell-free eukaryotic protein expression are provided.
|
|
| domain | founded_year | HQ Location |
Recombinant proteins are manufactured to support cancer immunotherapy efforts.
|
|
| domain | founded_year | HQ Location |
Specializes in the production of research reagents
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Prognomiq
Frequently Asked Questions about PrognomiQ
When was PrognomiQ founded?
PrognomiQ was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Where is PrognomiQ located?
PrognomiQ is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Who is the current CEO of PrognomiQ?
Philip Ma is the current CEO of PrognomiQ. They have also founded this company.
Is PrognomiQ a funded company?
PrognomiQ is a funded company, having raised a total of $102.24M across 4 funding rounds to date. The company's 1st funding round was a Series D of $34.32M, raised on Mar 15, 2022.
How many employees does PrognomiQ have?
As of Dec 31, 2021, the latest employee count at PrognomiQ is 24.
What does PrognomiQ do?
Founded in 2020 and headquartered in San Mateo, United States, PrognomiQ operates in the health technology sector. Diagnostic tests are developed by the company to identify cancer and other diseases at early stages. Proteomic data is integrated with genomic, metabolomic, and additional health information to support detection and treatment strategies. Operations focus on advancing personalized medicine through multi-omics approaches.
Who are the top competitors of PrognomiQ?
What products or services does PrognomiQ offer?
PrognomiQ offers Multi-Omics Tests and Proteomic Data Services.
Who are PrognomiQ's investors?
PrognomiQ has 10 investors. Key investors include Fidelity Investments, T. Rowe Price, Bruker, Seer, and Catalio Capital Management.